Else Marit Inderberg

1.4k total citations
54 papers, 1.0k citations indexed

About

Else Marit Inderberg is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Else Marit Inderberg has authored 54 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 36 papers in Immunology and 10 papers in Molecular Biology. Recurrent topics in Else Marit Inderberg's work include CAR-T cell therapy research (33 papers), Immunotherapy and Immune Responses (29 papers) and Cancer Immunotherapy and Biomarkers (22 papers). Else Marit Inderberg is often cited by papers focused on CAR-T cell therapy research (33 papers), Immunotherapy and Immune Responses (29 papers) and Cancer Immunotherapy and Biomarkers (22 papers). Else Marit Inderberg collaborates with scholars based in Norway, Germany and United Kingdom. Else Marit Inderberg's co-authors include Sébastien Wälchli, Gustav Gaudernack, Gunnar Kvalheim, Pierre Dillard, Hakan Köksal, Marit Renée Myhre, June H. Myklebust, Nadia Mensali, Theodossis A. Theodossiou and Steinar Aamdal and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Else Marit Inderberg

51 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Else Marit Inderberg Norway 18 602 542 336 110 106 54 1.0k
María Paula Roberti France 8 828 1.4× 559 1.0× 604 1.8× 93 0.8× 64 0.6× 11 1.4k
Nona Janikashvili France 18 491 0.8× 939 1.7× 287 0.9× 99 0.9× 78 0.7× 35 1.5k
Cristina Belgiovine Italy 17 401 0.7× 392 0.7× 447 1.3× 87 0.8× 40 0.4× 34 1.0k
Yongsheng Wang China 20 545 0.9× 282 0.5× 310 0.9× 85 0.8× 88 0.8× 54 927
Zhichen Sun China 19 648 1.1× 838 1.5× 454 1.4× 187 1.7× 75 0.7× 32 1.5k
Nadira Delhem France 20 277 0.5× 540 1.0× 331 1.0× 91 0.8× 102 1.0× 41 1.1k
Lopamudra Das Roy United States 16 599 1.0× 369 0.7× 605 1.8× 99 0.9× 81 0.8× 31 1.1k
Justin M. David United States 18 769 1.3× 558 1.0× 543 1.6× 49 0.4× 66 0.6× 30 1.4k
H. Mytrang United States 10 353 0.6× 454 0.8× 378 1.1× 59 0.5× 41 0.4× 14 963

Countries citing papers authored by Else Marit Inderberg

Since Specialization
Citations

This map shows the geographic impact of Else Marit Inderberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Else Marit Inderberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Else Marit Inderberg more than expected).

Fields of papers citing papers by Else Marit Inderberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Else Marit Inderberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Else Marit Inderberg. The network helps show where Else Marit Inderberg may publish in the future.

Co-authorship network of co-authors of Else Marit Inderberg

This figure shows the co-authorship network connecting the top 25 collaborators of Else Marit Inderberg. A scholar is included among the top collaborators of Else Marit Inderberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Else Marit Inderberg. Else Marit Inderberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Maggadóttir, Sólrún Melkorka, Svein Dueland, Nadia Mensali, et al.. (2024). Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer. Molecular Therapy. 32(6). 2021–2029. 4 indexed citations
3.
Inderberg, Else Marit, et al.. (2023). Determination of CAR T cell metabolism in an optimized protocol. Frontiers in Bioengineering and Biotechnology. 11. 1207576–1207576. 1 indexed citations
4.
Graczyk‐Jarzynka, Agnieszka, Klaudyna Fidyt, Hakan Köksal, et al.. (2023). Efficient chimeric antigen receptor targeting of a central epitope of CD22. Journal of Biological Chemistry. 299(7). 104883–104883. 3 indexed citations
5.
Maggadóttir, Sólrún Melkorka, Gunnar Kvalheim, Patrik Wernhoff, et al.. (2022). A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT). Frontiers in Oncology. 12. 1031232–1031232. 1 indexed citations
6.
Bounova, Gergana, Irantzu Anzar, Donjetë Simnica, et al.. (2022). Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination. Journal of Translational Medicine. 20(1). 419–419. 16 indexed citations
7.
Inderberg, Else Marit, Wenche Rasch, Steinar Aamdal, et al.. (2021). Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial. Frontiers in Immunology. 12. 663865–663865. 30 indexed citations
8.
Winge-Main, A., Sébastien Wälchli, & Else Marit Inderberg. (2020). T cell receptor therapy against melanoma—Immunotherapy for the future?. Scandinavian Journal of Immunology. 92(4). e12927–e12927. 9 indexed citations
9.
Inderberg, Else Marit & Sébastien Wälchli. (2020). Long-term surviving cancer patients as a source of therapeutic TCR. Cancer Immunology Immunotherapy. 69(5). 859–865. 15 indexed citations
10.
Dillard, Pierre, et al.. (2020). Colorectal cysts as a validating tool for CAR therapy. BMC Biotechnology. 20(1). 30–30. 3 indexed citations
11.
Dillard, Pierre, Hakan Köksal, Sólrún Melkorka Maggadóttir, et al.. (2020). Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy. Molecular Therapy. 29(3). 1199–1213. 21 indexed citations
12.
Brunsvig, Paal, Tormod Kyrre Guren, Marta Nyakas, et al.. (2020). Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer. Frontiers in Immunology. 11. 572172–572172. 35 indexed citations
13.
Mensali, Nadia, Amalie Grenov, Niladri Bhusan Pati, et al.. (2019). Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity. OncoImmunology. 8(3). 1558663–1558663. 22 indexed citations
14.
Köksal, Hakan, Pierre Dillard, Sólrún Melkorka Maggadóttir, et al.. (2019). Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma. Blood Advances. 3(8). 1230–1243. 39 indexed citations
15.
Theodossiou, Theodossis A., Muhammad Ali, Mantas Grigalavicius, et al.. (2019). Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT–tamoxifen hybrid therapy. npj Breast Cancer. 5(1). 13–13. 108 indexed citations
16.
Köksal, Hakan, Elisabeth Müller, Else Marit Inderberg, Øyvind S. Bruland, & Sébastien Wälchli. (2018). Treating osteosarcoma with CAR T cells. Scandinavian Journal of Immunology. 89(3). e12741–e12741. 39 indexed citations
17.
Huse, Kanutte, Arne Kolstad, Klaus Beiske, et al.. (2017). T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling. Clinical Cancer Research. 24(4). 870–881. 76 indexed citations
18.
Lilleby, Wolfgang, Gustav Gaudernack, Paal Brunsvig, et al.. (2017). Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. Cancer Immunology Immunotherapy. 66(7). 891–901. 79 indexed citations
19.
Walseng, Even, Hakan Köksal, Ibrahim M. Sektioglu, et al.. (2017). A TCR-based Chimeric Antigen Receptor. Scientific Reports. 7(1). 10713–10713. 79 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by María Paula Roberti Breakdown of academic impact, for papers by Nona Janikashvili Breakdown of academic impact, for papers by Cristina Belgiovine Breakdown of academic impact, for papers by Yongsheng Wang Breakdown of academic impact, for papers by Zhichen Sun Breakdown of academic impact, for papers by Nadira Delhem Breakdown of academic impact, for papers by Lopamudra Das Roy Breakdown of academic impact, for papers by Justin M. David Breakdown of academic impact, for papers by H. Mytrang
Rankless by CCL
2026